Table 2.
All interventional clinical trials of tocotrienols in breast cancer patients [74,75,76,77]. Accessed 28 May 2021.
| ClinicalTrials.gov Identifier | Intervention | Pathology | Treatment | Phase | No. of Patients | Dose; Duration | Outcome/Status |
|---|---|---|---|---|---|---|---|
| NCT01157026 | TRF | ER+ or PR+ | Tamoxifen | Pilot | 240 | 200 mg; daily/five years | Completed, 2010 |
| NCT04496492 | δ-Tocotrienol | Primary Breast Cancer | Preoperative observation | Phase II | 50 | 200 mg; 2×/day for 4 weeks | Completed, 2017 |
| NCT02909751 | Tocotrienol | Breast adenocarcinoma | Neoadjuvant chemotherapy | Phase II | 80 | 300 mg × 3 daily | Completed, 2019 |
| NCT03855423 | Tocovid Suprabio | Operable breast cancer | Preoperative observation | Phase Ib | 12 | 3 + 3 step up design | Unknown |